Physician profile
Ashley Long
NPI 1427707892
$2,116.05
in general payments reported to CMS, 2019-2025
13 companies · $147 in 2025
The $147 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $257 · 2023: $491 · 2024: $1,222 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $555.34 | 2023-2024 | |
| Genzyme Corporation | $290.25 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $211.58 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $148.30 | 2024 | Tremfya |
| Insmed, INC. | $136.92 | 2022 | |
| Amgen INC. | $132.49 | 2025 | Evenity |
| Ferring Pharmaceuticals INC. | $122.12 | 2024 | Rebyota |
| Ardelyx, INC. | $121.84 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $116.18 | 2024 | |
| Lucid Diagnostics INC. | $100.43 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.52 | 2024 | Entyvio |
| Ucb, INC. | $68.08 | 2024-2025 | Bimzelx |
| Scynexis, INC. | $16.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.